Repligen Co. (NASDAQ:RGEN – Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $168.01, but opened at $176.29. Repligen shares last traded at $172.44, with a volume of 272,942 shares.
Analysts Set New Price Targets
Several analysts have commented on the company. HC Wainwright reduced their price objective on Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Wolfe Research began coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Finally, Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus price target of $184.73.
Check Out Our Latest Stock Report on RGEN
Repligen Stock Down 2.8 %
Repligen (NASDAQ:RGEN – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same period in the previous year, the firm posted $0.23 EPS. Repligen’s revenue was up 9.7% on a year-over-year basis. Research analysts anticipate that Repligen Co. will post 1.54 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. UMB Bank n.a. grew its holdings in Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares during the period. Blue Trust Inc. increased its holdings in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares during the last quarter. Resources Management Corp CT ADV purchased a new position in shares of Repligen in the 3rd quarter worth $37,000. Quarry LP boosted its holdings in Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 239 shares during the last quarter. Finally, nVerses Capital LLC purchased a new stake in Repligen during the third quarter valued at about $45,000. Institutional investors and hedge funds own 97.64% of the company’s stock.
About Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
See Also
- Five stocks we like better than Repligen
- Top Stocks Investing in 5G Technology
- Kimberly-Clark: A Regal Opportunity in This Dividend King
- Following Congress Stock Trades
- 5 Stocks With Above-Market Yields Just Raised Payments Further
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Arista Networks’ Stock Plunge: Buying Opportunity for Investors?
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.